Which has better valuation and earnings, MRK or GSK?

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Merck & Co., Inc. $65.01B 5.71 $18.25B $1.25 120.30 GSK $43.07B 2.34 $7.54B $3.20 15.59

Is MRK or GSK more profitable?

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity. Company Net Margins Return on Equity Return on Assets Merck & Co., Inc. 4.77% 16.73% 6.13% GSK 14.56% 43.23% 11.60%

Does the media prefer MRK or GSK?

In the previous week, Merck & Co., Inc. had 25 more articles in the media than GSK. MarketBeat recorded 37 mentions for Merck & Co., Inc. and 12 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 1.21 beat GSK's score of 0.03 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 28 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.34 $7.54B $3.20 15.59 Novartis $54.53B 5.60 $13.98B $6.63 24.13

Is GSK or NVS more profitable?

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Novartis 23.29% 38.56% 14.47%

Does the media refer more to GSK or NVS?

In the previous week, Novartis had 30 more articles in the media than GSK. MarketBeat recorded 42 mentions for Novartis and 12 mentions for GSK. Novartis' average media sentiment score of 0.17 beat GSK's score of 0.03 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Novartis 13 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 14 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GSK or AZN?

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.34 $7.54B $3.20 15.59 Astrazeneca $61.37B 4.11 $10.23B $6.69 24.31

Is GSK or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Astrazeneca 17.02% 31.45% 13.20%

Does the media prefer GSK or AZN?

In the previous week, Astrazeneca had 3 more articles in the media than GSK. MarketBeat recorded 15 mentions for Astrazeneca and 12 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.03 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Astrazeneca 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.45 $15.51B $4.09 11.39 GSK $43.07B 2.34 $7.54B $3.20 15.59

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 61.20% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% GSK 14.56% 43.23% 11.60%

Does the media prefer NVO or GSK?

In the previous week, Novo Nordisk A/S had 11 more articles in the media than GSK. MarketBeat recorded 23 mentions for Novo Nordisk A/S and 12 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.63 beat GSK's score of 0.03 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 13 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, GSK or PFE?

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.34 $7.54B $3.20 15.59 Pfizer $63.70B 2.54 $7.77B $0.76 37.39

Is GSK or PFE more profitable?

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Pfizer 6.80% 19.63% 8.46%

Does the media refer more to GSK or PFE?

In the previous week, Pfizer had 84 more articles in the media than GSK. MarketBeat recorded 96 mentions for Pfizer and 12 mentions for GSK. Pfizer's average media sentiment score of 0.94 beat GSK's score of 0.03 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Pfizer 47 Very Positive mention(s) 24 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive

GSK (GSK) Competitors

$49.88 -0.99 (-1.95%)

As of 09/4/2026 03:58 PM Eastern

Compare

GSK vs. MRK, NVS, AZN, NVO, and PFE

Should you buy GSK stock or one of its competitors? GSK's main competitors and comparable companies include Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GSK compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Merck & Co., Inc. had 25 more articles in the media than GSK. MarketBeat recorded 37 mentions for Merck & Co., Inc. and 12 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 1.21 beat GSK's score of 0.03 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	28 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
GSK	14.56%	43.23%	11.60%

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 55.6% of its earnings in the form of a dividend. Merck & Co., Inc. has raised its dividend for 14 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Merck & Co., Inc. currently has a consensus price target of $148.60, indicating a potential downside of 1.18%. GSK has a consensus price target of $53.00, indicating a potential upside of 6.26%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Merck & Co., Inc. has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	5.71	$18.25B	$1.25	120.30
GSK	$43.07B	2.34	$7.54B	$3.20	15.59

Summary

Merck & Co., Inc. and GSK tied by winning 10 of the 20 factors compared between the two stocks.

How does GSK compare to Novartis?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. GSK pays out 55.6% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.34	$7.54B	$3.20	15.59
Novartis	$54.53B	5.60	$13.98B	$6.63	24.13

GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GSK currently has a consensus target price of $53.00, suggesting a potential upside of 6.26%. Novartis has a consensus target price of $141.20, suggesting a potential downside of 11.72%. Given GSK's higher probable upside, equities research analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, Novartis had 30 more articles in the media than GSK. MarketBeat recorded 42 mentions for Novartis and 12 mentions for GSK. Novartis' average media sentiment score of 0.17 beat GSK's score of 0.03 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Novartis	13 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	14 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Novartis	23.29%	38.56%	14.47%

Summary

Novartis beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Astrazeneca?

GSK (NYSE:GSK) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GSK currently has a consensus target price of $53.00, suggesting a potential upside of 6.26%. Astrazeneca has a consensus target price of $206.67, suggesting a potential upside of 27.09%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. GSK pays out 55.6% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.34	$7.54B	$3.20	15.59
Astrazeneca	$61.37B	4.11	$10.23B	$6.69	24.31

In the previous week, Astrazeneca had 3 more articles in the media than GSK. MarketBeat recorded 15 mentions for Astrazeneca and 12 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.03 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Astrazeneca	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Astrazeneca	17.02%	31.45%	13.20%

Summary

Astrazeneca beats GSK on 13 of the 19 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Novo Nordisk A/S had 11 more articles in the media than GSK. MarketBeat recorded 23 mentions for Novo Nordisk A/S and 12 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.63 beat GSK's score of 0.03 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

Novo Nordisk A/S has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Novo Nordisk A/S currently has a consensus price target of $64.94, indicating a potential upside of 39.38%. GSK has a consensus price target of $53.00, indicating a potential upside of 6.26%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 61.20% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
GSK	14.56%	43.23%	11.60%

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. GSK pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.45	$15.51B	$4.09	11.39
GSK	$43.07B	2.34	$7.54B	$3.20	15.59

Summary

Novo Nordisk A/S beats GSK on 14 of the 19 factors compared between the two stocks.

How does GSK compare to Pfizer?

GSK (NYSE:GSK) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Pfizer	6.80%	19.63%	8.46%

GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 6.26%. Pfizer has a consensus price target of $28.28, indicating a potential downside of 0.50%. Given GSK's higher probable upside, equities analysts plainly believe GSK is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.34	$7.54B	$3.20	15.59
Pfizer	$63.70B	2.54	$7.77B	$0.76	37.39

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.6%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. GSK pays out 55.6% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Pfizer had 84 more articles in the media than GSK. MarketBeat recorded 96 mentions for Pfizer and 12 mentions for GSK. Pfizer's average media sentiment score of 0.94 beat GSK's score of 0.03 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Pfizer	47 Very Positive mention(s)	24 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive

15.7% of GSK shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Pfizer beats GSK on 11 of the 19 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$100.91B	$12.25B	$7.25B	$23.65B
Dividend Yield	3.56%	2.59%	2.53%	3.73%
P/E Ratio	15.60	651.72	213.35	25.43
Price / Sales	2.34	754.76	625.09	20.84
Price / Cash	8.31	90.26	77.08	33.54
Price / Book	4.38	12.47	12.85	7.61
Net Income	$7.54B	$2.83B	$3.49B	$1.07B
7 Day Performance	-1.81%	4.03%	1.04%	-0.05%
1 Month Performance	-3.23%	6.29%	5.52%	-0.24%
1 Year Performance	23.44%	9.93%	24.39%	12.80%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.2252 of 5 stars	$49.88 -1.9%	$53.00 +6.3%	+26.1%	$100.91B	$43.07B	15.60	66,841	Trending News Dividend Cut Gap Down
MRK Merck & Co., Inc.	4.531 of 5 stars	$149.73 +1.3%	$147.60 -1.4%	+79.1%	$364.55B	$66.57B	119.78	75,000	Positive News Analyst Forecast
NVS Novartis	2.9779 of 5 stars	$161.17 +6.0%	$141.20 -12.4%	+24.5%	$290.15B	$56.69B	24.31	75,267	Trending News Options Volume Analyst Revision High Trading Volume
AZN Astrazeneca	4.6883 of 5 stars	$162.43 +0.2%	$206.67 +27.2%	-0.6%	$251.45B	$58.74B	24.28	96,100
NVO Novo Nordisk A/S	4.1028 of 5 stars	$45.11 -0.5%	$64.94 +44.0%	-17.0%	$202.40B	$46.80B	11.03	69,505	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Summary

How does GSK compare to Novartis?

Summary

How does GSK compare to Astrazeneca?

Summary

How does GSK compare to Novo Nordisk A/S?

Summary

How does GSK compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Do insiders and institutionals have more ownership in MRK or GSK?

Does the media prefer MRK or GSK?

Is MRK or GSK more profitable?

Is MRK or GSK a better dividend stock?

Do analysts prefer MRK or GSK?

Which has more volatility & risk, MRK or GSK?

Which has better valuation and earnings, MRK or GSK?

Summary

How does GSK compare to Novartis?

Is GSK or NVS a better dividend stock?

Which has stronger earnings & valuation, GSK or NVS?

Which has more risk & volatility, GSK or NVS?

Do institutionals & insiders hold more shares of GSK or NVS?

Do analysts rate GSK or NVS?

Does the media refer more to GSK or NVS?

Is GSK or NVS more profitable?

Summary

How does GSK compare to Astrazeneca?

Do institutionals and insiders believe in GSK or AZN?

Do analysts rate GSK or AZN?

Which has more volatility & risk, GSK or AZN?

Is GSK or AZN a better dividend stock?

Which has higher valuation & earnings, GSK or AZN?

Does the media prefer GSK or AZN?

Is GSK or AZN more profitable?

Summary

How does GSK compare to Novo Nordisk A/S?

Do institutionals and insiders believe in NVO or GSK?

Does the media prefer NVO or GSK?

Which has more risk and volatility, NVO or GSK?

Do analysts prefer NVO or GSK?

Is NVO or GSK more profitable?

Is NVO or GSK a better dividend stock?

Which has stronger earnings and valuation, NVO or GSK?

Summary

How does GSK compare to Pfizer?

Is GSK or PFE more profitable?

Which has more risk & volatility, GSK or PFE?

Do analysts recommend GSK or PFE?

Which has preferable valuation and earnings, GSK or PFE?

Is GSK or PFE a better dividend stock?

Does the media refer more to GSK or PFE?

Do insiders and institutionals hold more shares of GSK or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools